Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.66 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | APEX1 | P27695 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | NAAA | Q02083 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | RAD52 | P43351 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | CA9 | Q16790 | 2/20 | 0.35 |
| ▸ | ACHE | P22303 | 6/20 | 0.35 |
| ▸ | CES2 | O00748 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4975730 | 1.00 | TSHR (0.66) | TSHRTHRBPOLBAPEX1HTT | |
| SCHEMBL4984425 | 0.98 | TSHR (0.63) | TSHRTHRBPOLBAPEX1HTT | |
| SCHEMBL4981597 | 0.94 | TSHR (0.60) | TSHRTHRBPOLBAPEX1HTT | |
| SCHEMBL4982835 | 0.91 | TSHR (0.56) | TSHRTHRBPOLBAPEX1HTT | |
| SCHEMBL4985179 | 0.90 | TSHR (0.58) | TSHRTHRBPOLBAPEX1HTT | |
| SCHEMBL4977383 | 0.90 | TSHR (0.58) | TSHRTHRBPOLBAPEX1HTT | |
| SCHEMBL4980363 | 0.88 | TSHR (0.56) | TSHRTHRBPOLBAPEX1HTT | |
| SCHEMBL28679639 | 0.84 | TSHR (0.74) | TSHRTHRBPOLBAPEX1HTT | |
| SCHEMBL4983026 | 0.83 | TSHR (0.53) | TSHRTHRBPOLBAPEX1HTT | |
| SCHEMBL23530385 | 0.83 | TSHR (0.72) | TSHRTHRBPOLBAPEX1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080053835-A1 | Monomer Compound, Process for Producing the Same, Polymer Thereof, and Water-Based Curable Composition | KANSAI PAINT CO., LTD. (JP) | 2008-03-06 | — | — | US | disclosed |
| EP-1798218-A1 | MONOMER COMPOUND, PROCESS FOR PRODUCING THE SAME, POLYMER THEREOF, AND WATER-BASED CURABLE COMPOSITION | KANSAI PAINT CO., LTD. (JP) | 2007-06-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080053835-A1 | Monomer Compound, Process for Producing the Same, Polymer Thereof, and Water-Based Curable Composition | THEM6, PAM, WEE1 | TSHR 4460/4885THRB 3274/4885POLB 697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.